AbbVie 2Q Revenues: $13.9 billion (+34%) 2Q Earnings: $769 million (loss of $739 million 2Q20) Comments: Global revenues from the Immunology portfolio were $6.1 billion, up 15% with U.S. Humira sales of $4.3 billion, an increase of 7% while International Humira sales were $811 million, down 6% due to biosimilar competition; Global Skyrizi sales reached $674 million, +>100% and Global Rinvoq revenues were $378 million, +>100%. Global revenues from the Hematologic Oncology portfolio were ...